Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease
NCT02847650
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Females of non-childbearing potential and/or male subjects
- Clinical diagnosis of Parkinson's disease.
- Parkinson's Disease Hoehn & Yahr Stage I-III inclusive
- Treatment naïve or history of prior incidental treatment with dopaminergic agents for no more than 28 days
- Able to refrain from any Parkinson's disease medication not permitted by the protocol.
- History or presence of atypical Parkinsonian syndrome.
- Severe acute or chronic medical or psychiatric condition or cognitive impairment or
laboratory abnormality.
- Any condition possibly affecting drug absorption.
- Participation in other studies involving investigational drug(s), or treatment with
any investigational drug within 30 days.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Hershey, Pennsylvania
- Hot Springs, Arkansas
- Little Rock, Arkansas
- Carmichael, California
- Fresno, California
- Irvine, California
- La Jolla, California
- Loma Linda, California
- Los Angeles, California
- Oceanside, California
- San Francisco, California
- San Francisco, California
- San Luis Obiapo, California
- Walnut Creek, California
- Walnut Creek, California
- Denver, Colorado
- Fairfield, Connecticut
- New Haven, Connecticut
- Wilmington, Delaware
- Boca Raton, Florida
- Clearwater, Florida
- Fort Lauderdale, Florida
- Jacksonville, Florida
- Jacksonville, Florida
- Maitland, Florida
- Miami, Florida
- Naples, Florida
- Orlando, Florida
- Palm Beach Gardens, Florida
- Plantation, Florida
- St. Petersburg, Florida
- Tallahassee, Florida
- Tampa, Florida
- Atlanta, Georgia
- Conyers, Georgia
- Decatur, Georgia
- Savannah, Georgia
- Chicago, Illinois
- Chicago, Illinois
- Glenbrook, Illinois
- Kansas City, Kansas
- Lake Charles, Louisiana
- Shreveport, Louisiana
- Baltimore, Maryland
- Columbia, Maryland
- Frederick, Maryland
- Rockville, Maryland
- Boston, Massachusetts
- Boston, Massachusetts
- Ann Arbor, Michigan
- East Lansing, Michigan
- Grand Rapids, Michigan
- Southfield, Michigan
- Traverse City, Michigan
- Golden Valley, Minnesota
- Minneapolis, Minnesota
- St. Cloud, Minnesota
- Kansas City, Missouri
- Springfield, Missouri
- Omaha, Nebraska
- Omaha, Nebraska
- Henderson, Nevada
- Lebanon, New Hampshire
- Morristown, New Jersey
- New Brunswick, New Jersey
- Ridgewood, New Jersey
- Manhasset, New York
- Mineola, New York
- Mount Vernon, New York
- New York, New York
- New York, New York
- New York, New York
- Syracuse, New York
- Asheville, North Carolina
- Raleigh, North Carolina
- Oklahoma City, Oklahoma
- Oklahoma City, Oklahoma
- Norristown, Pennsylvania
- Sellersville, Pennsylvania
- Upland, Pennsylvania
- Knoxville, Tennessee
- Memphis, Tennessee
- Nashville, Tennessee
- Austin, Texas
- Dallas, Texas
- Houston, Texas
- San Antonio, Texas
- Salt Lake City, Utah
- Burlington, Vermont
- Richmond, Virginia
- Bellevue, Washington
- Spokane, Washington
- Wenatchee, Washington
- Milwaukee, Wisconsin
- Mar Del Plata, Buenos Aires
- Buenos Aires, Capital Federal
- Buenos Aires, Capital Federal
- Buenos Aires,
- Buenos Aires,
- Buenos Aires,
- Mexico City, Mexico D.F.
- Monterrey, Nuevo Leon
- Carolina,
- Phoenix, Arizona
- Phoenix, Arizona
- Boca Raton, Florida
- Miami, Florida
- Tampa, Florida
- Tampa, Florida
- Tampa, Florida
- Tampa, Florida
- Atlanta, Georgia
- Chicago, Illinois
- Kansas City, Kansas
- Boston, Massachusetts
- Boston, Massachusetts
- Asheville, North Carolina
- Cleveland, Ohio
- Toledo, Ohio
- Toledo, Ohio
- Greenville, Texas
- Houston, Texas
- Virginia Beach, Virginia
- CRÉTEIL Cedex,
- Créteil,
- Grenoble,
- La Tronche,
- Marseille,
- Marseille,
- Paris,
- Paris,
- Bochum, Nordrhein-westfalen
- Gera,
- Haag I. OB,
- Kassel,
- Marburg,
- Tuebingen,
- Ulm,
- Holon,
- Holon,
- Phoenix, Arizona
- Phoenix, Arizona
- Arcadia, California
- Loma Linda, California
- Newport Beach, California
- Newport Beach, California
- Pasadena, California
- Torrance, California
- Fairfield, Connecticut
- Boca Raton, Florida
- Gainesville, Florida
- Ormond Beach, Florida
- Tampa, Florida
- Vero Beach, Florida
- Atlanta, Georgia
- Chicago, Illinois
- Indianapolis, Indiana
- Boston, Massachusetts
- Marlton, New Jersey
- Amherst, New York
- Amherst, New York
- Orchard Park, New York
- Durham, North Carolina
- Durham, North Carolina
- Raleigh, North Carolina
- Cleveland, Ohio
- Toledo, Ohio
- Tulsa, Oklahoma
- Willow Grove, Pennsylvania
- Providence, Rhode Island
- Greenville, Texas
- Houston, Texas
- Kirkland, Washington
- Montreal, Quebec
- Montreal, Quebec
- Grenoble,
- La Tronche,
- Lille,
- Marseille,
- Marseille,
- Paris,
- Freiburg, Baden-wuerttemberg
- Bochum,
- Dresden,
- Muenchen,
- Ulm,
- Asahikawa, Hokkaido
- Morioka, Iwate
- Kita-ku, Osaka
- Suita, Osaka
- Bunkyo-ku, Tokyo
- Santiago de Compostela, A Coruna
- Hospitalet de Llobregat, Barcelona
- San Sebastian, Guipuzcoa
- Barcelona,
- Madrid,
- Valencia,
Descriptive Information | |||||||
---|---|---|---|---|---|---|---|
Brief Title ICMJE | Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease | ||||||
Official Title ICMJE | A 15-WEEK, PHASE 2, DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED, FLEXIBLE DOSE STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PF-06649751 IN SUBJECTS WITH EARLY STAGE PARKINSON'S DISEASE | ||||||
Brief Summary | The purpose of this study is to evaluate the efficacy, safety and tolerability of PF-06649751 in Parkinson's disease patients at early stage of the disease. | ||||||
Detailed Description | The B7601011 study has a randomized, double-blind, placebo-controlled parallel group design. Approximately 88 subjects will be randomized to 2 treatment groups. Each subject will participate in the study for approximately 23 weeks including a 30 day screening period, 15 week double blind treatment period, and an approximately 28 day follow-up period. | ||||||
Study Type ICMJE | Interventional | ||||||
Study Phase ICMJE | Phase 2 | ||||||
Study Design ICMJE | Allocation: Randomized Masking: Triple (Participant, Care Provider, Investigator) Primary Purpose: Treatment | ||||||
Condition ICMJE | Parkinson Disease | ||||||
Intervention ICMJE |
| ||||||
Study Arms ICMJE |
| ||||||
Publications * | Riesenberg R, Werth J, Zhang Y, Duvvuri S, Gray D. PF-06649751 efficacy and safety in early Parkinson's disease: a randomized, placebo-controlled trial. Ther Adv Neurol Disord. 2020 Mar 6;13:1756286420911296. doi: 10.1177/1756286420911296. eCollection 2020. | ||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||||||
Recruitment Information | |||||||
Recruitment Status ICMJE | Terminated | ||||||
Actual Enrollment ICMJE | 57 | ||||||
Original Estimated Enrollment ICMJE | 88 | ||||||
Actual Study Completion Date ICMJE | January 29, 2018 | ||||||
Actual Primary Completion Date | January 29, 2018 (Final data collection date for primary outcome measure) | ||||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| ||||||
Sex/Gender ICMJE |
| ||||||
Ages ICMJE | 45 Years to 80 Years (Adult, Older Adult) | ||||||
Accepts Healthy Volunteers ICMJE | No | ||||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||||
Listed Location Countries ICMJE | France, Germany, Israel, United States | ||||||
Removed Location Countries | |||||||
Administrative Information | |||||||
NCT Number ICMJE | NCT02847650 | ||||||
Other Study ID Numbers ICMJE | B7601011 2016-001575-71 ( EudraCT Number ) | ||||||
Has Data Monitoring Committee | Yes | ||||||
U.S. FDA-regulated Product |
| ||||||
IPD Sharing Statement ICMJE |
| ||||||
Responsible Party | Pfizer | ||||||
Study Sponsor ICMJE | Pfizer | ||||||
Collaborators ICMJE | Not Provided | ||||||
Investigators ICMJE |
| ||||||
PRS Account | Pfizer | ||||||
Verification Date | October 2020 | ||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |